Rakshana Manikandan,
M. Mala,
G. Manikandan,
Prakash Vaithyanathan,
- Trustee, Tagore Educational Trust, Chennai, Tamil Nadu, India
- Chairperson and Managing Trustee, Tagore Educational Trust, Chennai, Tamil Nadu, India
- Secretary, Tagore Educational Trust, Chennai, Tamil Nadu, India
- Science Teacher and Innovator, Chennai, Tamil Nadu, India
Abstract
Psoriasis is a chronic, hyper-proliferative and inflammatory skin disease. Increased levels of the calmodulin-containing enzyme, namely, phosphorylase kinase (PhK), were observed in the human epidermis of the active psoriasis cases. Thus PhK is a potential biomarker for the diagnosis and progression of the skin disease, namely, psoriasis. The search for the potential molecules that could supress the over expression of PhK is underway and any break-through in this direction leads to the alleviation of the suffering of the patients infected with Psoriasis. Fundamental studies revealed curcumin to be a potential inhibitor of PhK. In our study we report that the water soluble edible molecule from the flower petals of Butea monosperma namely, isobutrin, outperforms curcumin, in terms of the intensity of molecular level interactions of isobutrin with the amino acids related to PhK. Molecular docking studies revelated stonger interactions of isobutrin with amino acids characteristics of PhK and the interactions are much stronger than those exhbited with curcumin with similar amino acids of PhK. Thus the therapeutic potential of isobutrin is hypothesised. The results need to be further strengthened by the animal model studies that are underway.
Keywords: Curcumin, isobutrin, molecular docking, phosphorylase kinase, psoriasis
[This article belongs to International Journal of Cheminformatics ]
Rakshana Manikandan, M. Mala, G. Manikandan, Prakash Vaithyanathan. An Insilico Study of Isobutrin and Phosphorylase Kinase – A Ray of Hope for Psoriasis Patients – Clinical Hypothesis. International Journal of Cheminformatics. 2024; 02(01):1-8.
Rakshana Manikandan, M. Mala, G. Manikandan, Prakash Vaithyanathan. An Insilico Study of Isobutrin and Phosphorylase Kinase – A Ray of Hope for Psoriasis Patients – Clinical Hypothesis. International Journal of Cheminformatics. 2024; 02(01):1-8. Available from: https://journals.stmjournals.com/ijci/article=2024/view=177776
References
- Heng MCY. Song MK, Heng MK. Elevated phosphorylase kinase activity in psoriatic epidermis: correlation with increased phosphorylation and psoriatic activity. Br J Dermatol. 1994; 130; 298-306.
- Heng MCY. Signaling pathways targeted by curcumin in acute and chronic injury: burns and photo-damaged skin. Int J Dermatol. 2013; 52: 531–43p.
- Heng MCY, Song MK, Harker J, et al. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol. 2000; 143: 937-49p.
- Herman A, Herman AP. Topically used herbal products for the treatment of psoriasis – Mechanism of action, drug delivery, clinical studies. Planta Med. 2016; 82: 1447–55p.
- Begum J, Skamnaki VT, Moffatt C, et al. An evaluation of indirubin analogues as phosphorylase kinase inhibitors. J Mole Graph Model. 2015; 61:231–42p.
- Kumar B, Sahoo PK. Augmented transdermal delivery of curcumin for the effective management of plaque psoriasis – design, formulation, characterisation, and in vivo studies. AAPS PharmSciTech. 2023; 24: 134.
- Ely H. Is psoriasis a bowel disease? Successful treatment with bile acids and bioflavonoids suggests it is. Clin Dermatol. 2018; 36: 376–89p.
- Sun J, Zhao Y, Hu J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting il-1beta and il-6 production in mice. PLoS ONE. 2013; 8(6): e67078.
- Sun J, Han JZ, Zhao Y, et al. Curcumin induces apoptosis in tumor necrosis factor-alpha-treated HaCaT cells. Int Immunopharmacol. 2012; 13: 170-74p.
- Bantia S, Parker C, Upshaw R, et al. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes—A novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. Inter Immunopharmacol. 2010; 10:784-90p.
- https://pubchem.ncbi.nlm.nih.gov/compound/Butrin
- Konakanchi VC, Kar BR, Sathishkumar D, et al. Small Molecules in the Management of Psoriasis and Psoriatic Arthritis. Indian Journal of Dermatology. 2024; 69(3):249-55p.
- Matade R, Harne S, Kale S, et al., Therapeutic landscape of natural products and emulgel in psoriasis. International Journal of Pharmaceutical Chemistry and Analysis, 2024;11(1):25–34p.
- Milind Patil1, Nikhil Chaudhari2, Rajan Chaudhari3, et al., A prospective, open-label, non-randomised clinical trial to evaluate the safety and efficacy of Imupsora in the treatment of Psoriasis. Journal of Ayurveda and Integrated Medical Sciences. 2024; 9 (5) 1-10.
- Cieszkowska J, Otręba K, Czupryńska K, et al. Therapeutic potential of curcuminoids in the treatment of selected autoimmune diseases. Journal of Education, Health and Sport. 2024; 67: 1-16p.
- Mohammadi SG, Kafeshani M, Bagherniya M, et al. Exploring Curcumin’s healing properties in the treatment of atopic dermatitis. Food Bioscience. 2024; 59: 104144.
- Rakshana Manikandan, M. Mala, G. Manikandan, Prakash Vaithyanathan. Butrin Tackles Retinoblastoma – A Clinical Hypothesis. International Journal of Advance in Molecular Engineering. 2024; 02(01):26-30.
- Vaithyanathan, P. Analysis of an Insilico Interaction by a Curcumin Derivative Specially only with the akt1 molecule but not AKT2. DOI: https://doi.org/10.21203/rs.3.rs-3156936/v1. Preprint. 2023.
| Volume | 02 |
| Issue | 01 |
| Received | 16/09/2024 |
| Accepted | 19/09/2024 |
| Published | 10/10/2024 |
| Publication Time | 24 Days |
Login
PlumX Metrics